AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure, Inc. (ATRC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript